Actavis sees 2Q loss but Warner deal has reached final stages
This article was originally published in Scrip
Generic drug developer Actavis has posted a second quarter loss of $4.27 per share, despite reporting a 47% increase in revenues, because of "restructuring costs." The Parsippany, New Jersey-based firm, previously known as Watson Pharmaceuticals, said the costs arose from the 2009 acquisition of UK drug maker Arrow. The combined assets were subsequently restructured from one global reporting unit into four new reporting units.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.